Ketamine in pediatric TRD patients

Clinical Score: 0.700 Price: $0.50 treatment-resistant depression pediatric patients Status: proposed

What This Experiment Tests

Clinical experiment designed to assess clinical efficacy targeting N/A in pediatric patients. Primary outcome: antidepressant efficacy and safety

Description

Clinical assessment of ketamine and esketamine safety and efficacy in pediatric patients with treatment-resistant depression. This specialized population study examined the use of NMDA receptor antagonists in children and adolescents who had not responded to standard antidepressant treatments. The research focused on age-appropriate dosing, developmental considerations, and the unique risk-benefit profile in younger patients, including assessment of potential impacts on developing neural systems and long-term safety concerns specific to pediatric populations.

TARGET GENE
N/A
MODEL SYSTEM
pediatric patients
ESTIMATED COST
$0
TIMELINE
0 months
PATHWAY
NMDA receptor signaling
SOURCE
extracted_from_pmid_41935374
PRIMARY OUTCOME
antidepressant efficacy and safety

Scoring Dimensions

Info Gain 0.00 (25%) Feasibility 0.00 (20%) Hyp Coverage 0.00 (20%) Cost Effect. 0.00 (15%) Novelty 0.00 (10%) Ethical Safety 0.00 (10%) 0.700 composite

📖 Wiki Pages

NMDA Receptor Subunit NR2B (GRIN2B)proteinNMDA Receptor Subunit NR1 (GRIN1)proteinNMDA Receptor ProteinproteinNMDA Receptor NR2A ProteinproteinNMDA ReceptorproteinNMDA ReceptorentityNMDA Receptor NeuronscellTreatmentsindexDepression (Major Depressive Disorder)disease

Protocol

Pediatric-adapted ketamine/esketamine administration with specialized monitoring protocols

Expected Outcomes

Effective antidepressant response with acceptable pediatric safety profile

Success Criteria

Demonstration of efficacy with minimal adverse effects appropriate for pediatric use

Related Hypotheses (0)

No related hypotheses

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.